UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2372-1
Program Prior Authorization/Medical Necessity
Medication Qfitlia® (fitusiran)
P&T Approval Date 5/2025
Effective Date 7/1/2025
1. Background:
Qfitlia (fitusiran) is an antithrombin-directed small interfering ribonucleic acid indicated for
routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric
patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX
inhibitors.
2. Coverage Criteriaa:
A. Hemophilia A With Inhibitors
1. Initial Authorization
a. Qfitlia will be approved based on all of the following criteria
(1) Diagnosis of hemophilia A
-AND-
(2) Patient has developed high-titer factor VIII inhibitors ( > 5 Bethesda units [BU])
-AND-
(3) Patient is 12 years of age or older
-AND-
(4) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)
Authorization of therapy will be issued for 12 months.
2. Reauthorization
a. Documentation of positive clinical response to Qfitlia therapy
Authorization will be issued for 12 months.
B. Hemophilia A Without Inhibitors
1. Initial Authorization
© 2025 UnitedHealthcare Services Inc.
1
a. Qfitlia will be approved based on all of the following criteria
(1) One of the following:
(a) Both of the following:
i. Diagnosis of severe hemophilia A
-AND-
ii. Documentation of endogenous factor VIII levels less than 1% of normal
factor VIII (< 0.01 IU/mL)
-OR-
(b) Both of the following:
i. One of the following
1. Both of the following
a. Diagnosis of moderate hemophilia A
-AND-
b. Documentation of endogenous factor VIII level >1% < 5% (greater
than or equal to 0.01 IU/mL to less than 0.05 IU/mL)
-OR-
2. Both of the following
a. Diagnosis of mild hemophilia A
-AND-
b. Documentation of endogenous factor VIII level > 5% (greater than
or equal to 0.05 IU/mL)
-AND-
ii. Submission of medical records (e.g., chart notes, laboratory values)
documenting a failure to meet clinical goals (e.g., continuation of
spontaneous bleeds, inability to achieve appropriate trough level, previous
history of inhibitors) after a trial of prophylactic factor VIII replacement
products
-OR-
(c) All of the following:
© 2025 UnitedHealthcare Services Inc.
2
i. Patient is currently on Qfitlia therapy
-AND-
ii. Diagnosis of hemophilia A
-AND-
iii. Patient has not received a manufacturer supplied sample at no cost in
prescriber office, or any form of assistance from the HemAssist or Sanofi
Patient Support (e.g., sample card which can be redeemed at a pharmacy
for a free supply of medication) as a means to establish as a current user of
Qfitlia*
-AND-
(2) Patient is 12 years of age or older
-AND-
(3) Qfitlia is prescribed for the prevention of bleeding episodes (i.e., routine
prophylaxis)
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from
the HemAssist or Sanofi Patient Support shall be required to meet initial authorization criteria as
if patient were new to therapy.
Authorization of therapy will be issued for 12 months.
2. Reauthorization
a. Qfitlia will be approved based on the following criterion:
(1) Documentation of positive clinical response to Qfitlia therapy
Authorization will be issued for 12 months.
C. Hemophilia B With Inhibitors
1. Initial Authorization
a. Qfitlia will be approved based on all of the following criteria
(1) Diagnosis of hemophilia B
-AND-
(2) Patient has developed high-titer factor IX inhibitors ( > 5 Bethesda units [BU])
© 2025 UnitedHealthcare Services Inc.
3
-AND-
(3) Patient is 12 years of age or older
-AND-
(4) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)
Authorization of therapy will be issued for 12 months.
2. Reauthorization
a. Documentation of positive clinical response to Qfitlia therapy
Authorization will be issued for 12 months.
D. Hemophilia B Without Inhibitors
1. Initial Authorization
a. Qfitlia will be approved based on all of the following criteria
(1) One of the following:
(a) Both of the following:
i. Diagnosis of severe hemophilia B
-AND-
ii. Documentation of endogenous factor IX levels less than 1% of normal
factor IX (< 0.01 IU/mL)
-OR-
(b) Both of the following:
i. One of the following
1. Both of the following
a. Diagnosis of moderate hemophilia B
-AND-
b. Documentation of endogenous factor IX level >1% < 5% (greater
than or equal to 0.01 IU/mL to less than 0.05 IU/mL)
-OR-
© 2025 UnitedHealthcare Services Inc.
4
2. Both of the following
a. Diagnosis of mild hemophilia B
-AND-
b. Documentation of endogenous factor IX level > 5% (greater than or
equal to 0.05 IU/mL)
-AND-
ii. Submission of medical records (e.g., chart notes, laboratory values)
documenting a failure to meet clinical goals (e.g., continuation of
spontaneous bleeds, inability to achieve appropriate trough level, previous
history of inhibitors) after a trial of prophylactic factor IX replacement
products
-OR-
(c) All of the following:
i. Patient is currently on Qfitlia therapy
-AND-
ii. Diagnosis of hemophilia B
-AND-
iii. Patient has not received a manufacturer supplied sample at no cost in
prescriber office, or any form of assistance from the HemAssist or Sanofi
Patient Support (e.g., sample card which can be redeemed at a pharmacy
for a free supply of medication) as a means to establish as a current user of
Qfitlia*
-AND-
(2) Patient is 12 years of age or older
-AND-
(3) Qfitlia is prescribed for the prevention of bleeding episodes (i.e., routine
prophylaxis)
* Patients requesting initial authorization who were established on therapy via the receipt of a
manufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from
the HemAssist or Sanofi Patient Support shall be required to meet initial authorization criteria as
if patient were new to therapy.
© 2025 UnitedHealthcare Services Inc.
5
Authorization of therapy will be issued for 12 months.
2. Reauthorization
a. Qfitlia will be approved based on the following criterion:
(1) Documentation of positive clinical response to Qfitlia therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Qfitlia® [package insert]. Cambridge, MA: Genzyme Corporation; March 2025.
2. Young G, Srivastava A, Kavakli K, et al. Efficacy and safety of fitusiran prophylaxis in people
with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label,
randomised phase 3 trial. Lancet. 2023;401(10386):1427-1437. doi:10.1016/S0140-
6736(23)00284-2
3. Srivastava A, Rangarajan S, Kavakli K, et al. Fitusiran prophylaxis in people with severe
haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label,
randomised, phase 3 trial. Lancet Haematol. 2023;10(5):e322-e332. doi:10.1016/S2352-
3026(23)00037-6
Program Prior Authorization/Medical Necessity - Qfitlia (fitusiran)
Change Control
5/2025 New program
© 2025 UnitedHealthcare Services Inc.
6